title: Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron.
abstract: In chronic inflammation it is reported that serum iron is depleted and hepatic iron is increased because of reticuloendothelial system iron blockade. However, recent studies indicate that hepatic parenchymal cells increase the uptake of transferrin-bound iron after in vivo stimulation with bacterial lipopolysaccharide, suggesting that endotoxemia itself or lipopolysaccharide-induced production of inflammation-related cytokines may also be responsible for this phenomenon. In this study the actions of inflammation-related cytokines on the synthesis of iron-binding proteins (transferrin and ferritin) and transferrin receptor and the uptake of transferrin-bound iron were investigated in a human hepatoblastoma cell line, HepG2, which is the most commonly used cell line for examining the regulation of hepatic protein synthesis by cytokines. The cells were exposed to interleukin-1 beta, interleukin-6 or tumor necrosis factor-alpha separately for 24 hr. In each cytokine treatment group, the level of transferrin, which is secreted into the conditioned medium, was found to be decreased compared with that of untreated cells. On the other hand, the biosynthesis of ferritin was markedly elevated after the same treatment. This increase in ferritin by cytokine treatment was diminished when deferoxamine was used concomitantly to deplete intracellular chelatable iron. After stimulation with interleukin-1 beta, interleukin-6 or tumor necrosis factor-alpha, 59Fe-labeled transferrin uptake into the cells was increased by 36%, 48%, or 18%, respectively, and this uptake was inhibited by the addition of excess unlabeled transferrin. A binding study with 125I-labeled diferric transferrin revealed that the three cytokines increased the number of transferrin receptors on the cell surface by 1.15-fold to 1.35-fold.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hirayama
authors.forename: Y
authors.initials: Y
authors.lastname: Kohgo
authors.forename: H
authors.initials: H
authors.lastname: Kondo
authors.forename: N
authors.initials: N
authors.lastname: Shintani
authors.forename: K
authors.initials: K
authors.lastname: Fujikawa
authors.forename: K
authors.initials: K
authors.lastname: Sasaki
authors.forename: J
authors.initials: J
authors.lastname: Kato
authors.forename: Y
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology; D016207:Cytokines / Q000502:physiology*; D005293:Ferritins / Q000096:biosynthesis; D006801:Humans; D007375:Interleukin-1 / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D007501:Iron / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology; D011990:Receptors, Transferrin / Q000096:biosynthesis; D014168:Transferrin / Q000096:biosynthesis; D014407:Tumor Cells, Cultured / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
chemical_list: D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D011990:Receptors, Transferrin; D014168:Transferrin; D014409:Tumor Necrosis Factor-alpha; D005293:Ferritins; D007501:Iron